New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada

Bodoarca Rebecca; Yeung Roseanne O.; Lau Darren

首页> 外文期刊>Canadian journal of diabetes >New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada

【24h】

New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada

机译：New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Objectives: Recent diabetes guidelines call for prescribing sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for end-organ indications (cardiovascular disease [CVD], heart failure and chronic kidney disease) and for primary prevention of CVD in adults with multiple risk factors. Our aim was to assess the effect of new guidelines on the prevalence of SGLT2i/GLP-1RAeeligible adults, and their current rates of SGLT2i/GLP-1RA use. Methods: A cross-sectional study was conducted of Canadian adults (age >= 18 years) with diabetes on June 30, 2020, using electronic medical record data from primary care practices in 5 provinces (Alberta, Manitoba, Newfoundland, Ontario and Quebec). Indications were determined from comorbidities, lab values and cardiovascular risk factors. Results: End-organ indications were present in 34.1% of adults for SGLT2i and in 17.1% for GLP-1RA (CVD only). Rates of SGLT2i and GLP-1RA use were only 14.0% and 4.3%, respectively, in those with end-organ indications. The majority of these individuals had glycated hemoglobin <= 7.0%. The combination of end-organ and primary prevention indications increased eligibility for SGLT2i to 62.6%, and for GLP-1RA to 59.1%. Conclusions: The implications of this sizeable reclassification of adults as SGLT2i/GLP-1RA indicated on health-care budgets and cost-effectiveness requires further study. In the meantime, targeted efforts are necessary to improve SGLT2i/GLP-1RA use in those with end-organ indications that have robust evidence of cardiovascular and kidney benefit from newer agents. (c) 2022 Canadian Diabetes Association.

著录项

来源
《Canadian journal of diabetes》 |2022年第7期|691-698|共8页
作者
Bodoarca Rebecca; Yeung Roseanne O.; Lau Darren;
展开▼
作者单位

University of Alberta,Univ Alberta;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类内分泌腺疾病及代谢病;
关键词
Diabetes; GLP-1 receptor agonist; prescribing patterns; primary care; primary prevention; SGLT-2 inhibitor; CHRONIC DISEASE SURVEILLANCE; ISCHEMIC-HEART-DISEASE; ADMINISTRATIVE DATA; IDENTIFYING PATIENTS; DATABASE;

New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada

摘要

著录项

相关主题

期刊订阅